ATRX and cancer: Here we report that the chromatin remodeling enzyme ATRX is required for quiescent cancer cells to progress into senescence triggered by MDM2 loss and by the treatment of cells with CDK4i or doxorubicin, a p53-independent and a p53-dependent DNA-damage associated pathway, respectively.